Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge
It is estimated that about 1 in 5 people will develop cancer in their lifetime. Receiving a cancer diagnosis can feel like your life, and the lives of those around you, have been flipped upside down. In honor of #WorldCancerDay, we're participating in the Union for International Cancer Control (UICC) 's Upside Down Challenge to rally behind the unique voices of every patient and family member impacted by cancer and help bring much-needed awareness to this challenging disease. Learn how you can get involved today and use the hashtag #UnitedByUnique
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP
On June 4, 2025, Edelson Lechtzin LLP announced that it has initiated an inquiry into whether the healthcare technology company, Semler Scientific, Inc. (NASDAQ:SMLR), misled investors about its business operations regarding claims tied to its QuantaFlo diagnostic device. A doctor in focus surrounded by colleagues in a hospital setting. In an annual report filed by Semler Scientific, Inc. (NASDAQ:SMLR) on February 28, 2025, the company disclosed that the U.S. Department of Justice (DOJ) was evaluating a potential False Claims Act case. The report triggered immediate market reaction, with the company's shares plummeting by 9.4% to close at $38.89 on March 3. Initiating the inquiry, Edelson Lechtzin LLP has asked for the public and stakeholders' help. Edelson urges those with non-public information regarding Semler Scientific, Inc. (NASDAQ:SMLR) to come forward and assist them in the investigation. It also encourages the company's investors who have suffered losses to follow the inquiry to learn more. The investor confidence has been significantly fluctuating since the disclosure. The stock's performance, which gained 6.49% last month, declined by 13.46% last week. The California-based company, Semler Scientific, Inc. (NASDAQ:SMLR), is known for developing non-invasive medical tools, with QuantaFlo being its most prominent product. Focusing on early disease detection and chronic condition management, the company has positioned itself between healthcare and technology. While we acknowledge the potential of SMLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
Yahoo
18 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
